The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement by 理쒖쭊�쁺 et al.
icine®
ONAL STUDYMed
OBSERVATIThe Role of Neoadjuvant Chemoradiation Therapy in
Patients With Borderline Resectable Pancreatic Cancer With
Isolated Venous Vascular InvolvementngJin Ho Lee, MD, Chang Moo Kang, MD, PhD, Seu
Su
therapeutic (downstaging) effect.
(Medicine 94(31):e1233)
operative mortality ra
pancreatectomy with p
vein (SMV) resection w
Editor: Wenfu Tang.
Received: March 3, 2015; revised: May 28, 2015; accepted: July 6, 2015.
From the Division of Pancreaticobiliary Cancer Clinic, Department of
Surgery, Institute of Gastroenterology, Severance Hospital, Yonsei Uni-
versity College of Medicine, Seoul, Korea (JHL, CMK, HKH, WJL);
Division of Gastroenterology, Department of Internal Medicine and Yonsei
Institute of Gastroenterology, Severance Hospital, Yonsei University College
of Medicine, Seoul, Korea (SMB); Department of Radiology, Institute of
Gastroenterology, Severance Hospital, Yonsei University College of
Medicine, Seoul, Korea (JYC); Department of Radiation Oncology,
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
(JSS); and Division of Hepatobiliary and Pancreas, Department of Surgery,
CHA Bundang Medical Center, CHA University, Seongnam, Korea (SHC)
Correspondence: Chang Moo Kang, Department of Surgery, Severance
Hospital, Yonsei University College of Medicine, 50 Yonsei-Ro,
Seodaemun-Ku, Seoul 120-752, Korea (e-mail: cmkang@yuhs.ac).
The authors have no conflicts of interest to disclose.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-ShareAlike 4.0 License, which
allows others to remix, tweak, and build upon the work non-commercially,
as long as the author is credited and the new creations are licensed under
the identical terms.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000001233
Medicine  Volume 94, Number 31, August 2015hD, Jin Young
Jin Sil Seong, MD, PhD, Ho Kyoung Hwang, MD,
Abstract: The rationale for neoadjuvant chemoradiation therapy
(Neo-CRT) and the definition of borderline resectable pancreatic cancer
(BRPC) are still controversial. In particular, surgical treatment of BRPC
with isolated venous vascular involvement (IVVI) is debatable.
From January 2000 to December 2013, 84 patients diagnosed with
BRPC according to NCCN guidelines were identified, and 70 patients
were found to have BRPC with IVVI. We divided all 70 patients into 3
groups: surgery first without Neo-CRT (Group 1); pancreatectomy
following Neo-CRT (Group 2); and no operation following Neo-
CRT (Group 3). Patient characteristics including oncologic outcomes
were analyzed for each of the 3 patients groups.
Thirty-seven patients were female and 33 were male, with a mean
age of 61.7 9.74 years. Among the 70 BRPC patients with IVVI, 28
patients (40%) belonged to Group 1, 30 patients (42.9%) belonged to
Group 2, and 12 patients (17.1%) belonged to Group 3. Pathological
tumor size (P< 0.001), pT stage (P¼ 0.001), pTNM stage (P¼ 0.002),
combined vascular resection (P¼ 0.003), completeness of adjuvant
therapy (P¼ 0.004) were found to be statistically significantly different
between Groups 1 and 2. In addition, disease-free survival (P¼ 0.055)
and disease-specific survival (DSS) (P¼ 0.006) were improved in
Group 2. Interestingly, when comparing DSS, there was no statistically
significant difference between Groups 1 and 3 (P¼ 0.991).
The clinical practice of pancreatectomy following Neo-CRT in
BRPC with IVVI provided favorable oncologic outcomes. The effect
of Neo-CRT in BRPC with IVVI may be multifactorial, providing
proper patient selection, complete adjuvant chemotherapy, and potentialMin Bang, MD, P Choi, MD, PhD,
ng Hoon Choi, MD, and Woo Jung Lee, MD, PhD
Abbreviations: BRPC = borderline resectable pancreatic cancer,
CT = computerized tomography, DFS = disease-free survival, DSS
= disease-specific survival, Gy = gray (a derived unit of ionizing
radiation dose in the International System of Units), IVVI =
isolated venous vascular involvement, LOH = length of hospital
day, Neo-CRT = neoadjuvant chemoradiation therapy, NVR =
without vein resection, OP = operation, PC = pancreatic cancer, PD
= pancreaticoduodenectomy, PET = positron emission tomography,
PV = portal vein, SMV = superior mesenteric vein, SV = splenic
vein, VR = with vein resection.
INTRODUCTION
P ancreatic cancer (PC) is a fatal malignant disease in gastro-intestinal digestive systems and the fifth leading cause of
cancer death in Korea.1 Until now, margin-negative pancrea-
tectomy is the only known cure for the disease; however, PCs
are often found to be already locally advanced or distantly
metastasized. With such resection rate is only up to 10% to
20%.2,3 Even if the cancer is resectable, R0 resection rate is only
32% to 71%.4–7 It has also been reported that, when potentially
curative resection is achieved, the 5-year survival rate is as low
as 8% to 25%6,8 due to high loco-regional recurrence rate and
distant metastasis to organs such as the liver.9,10 Therefore,
treatment for pancreas cancer requires a multimodal approach to
cure the systemic disease, for which surgery alone is not
enough.
Many institutions have studied adjuvant therapy to prevent
and treat high loco-regional recurrence and distant metastasis
occurring after pancreas cancer operation. And their studies11–
13 reported that adjuvant chemoradiation therapy after pancreas
cancer operation increased patient survival. However, post-
operative adjuvant therapy was not able to be performed to
24% 56% of patients.7,11,14,15 The most common causes of
low adjuvant chemoradiation therapy were reported to be
delayed recovery after major surgery, medical comorbidity,
and disease progression.
For these reasons, recent researches have focused on
preoperative neoadjuvant therapy rather than postoperative
adjuvant therapy as treatment for PC in order to increase
survival rates.14,16–22 In case of patients who underwent neoad-
juvant chemoradiation therapy (Neo-CRT), it was reported that
resection rate increased to 41% to 100%, and R0 resection rate
increased to 84% to 96%, with an excellent median survival
time of 21 to 40 months.16,21,23 In addition, over the past 20
years, advancement in surgical technique and perioperative
management have brought improvements in surgical outcomes
of patients with venous vascular involvement in PC. In past,te was greater than 15% to 21% when
ortal vein (PV) or superior mesenteric
as performed.24–26 Now, however, there
www.md-journal.com | 1
CT image. Cancer staging was determined according to the
FIGURE 2. Oncologic outcomes according to sequence of Neo-
CRT therapy and surgery. (A) Disease-free survival and (B) disease-
specific survival. Survival differences according to sequence of
Neo-CRT and surgery (DSS: P¼0.006; DFS: P¼0.055); Neo-
Lee et al Medicine  Volume 94, Number 31, August 2015is reportedly no difference in surgical mortality for pancrea-
tectomy with or without PV or SMV resection.27 Kelly et al28
reported that vein involvement was not predictive of disease-
free or overall survival, and the oncological outcome was not
different between vein resection combined with pancreatico-
duodenectomy (PD) and PD without combined vein resection.
Therefore, while cases with venous vascular involvement were
previously considered unresectable due to limitations of surgi-
cal technique, vascular combined resection has now become
technically feasible and safe.29 Thus, many pancreatic surgeons
may regard BRPC with isolated venous vascular involvement
(IVVI) as resectable rather than borderline resectable. For this
reason, there are conflicting opinions on treatment for BRPC,
especially with IVVI.
In this study, we reviewed the clinical practice of treatment
for PC with IVVI, verifying the effectiveness of Neo-CRT for
patients of BRPC with IVVI.
MATERIALS AND METHODS
Study Population
Medical records from January 2000 to December 2013
were reviewed, 84 patients with BRPC according to NCCN
guidelines were selected30 and 70 patients were noted to have
IVVI. We divided all 70 patients into 3 groups (Figure 1):
surgery without neoadjuvant chemoradiation (Neo-CRT)
(Group 1); PD following Neo-CRT (Group 2); and no operation
following Neo-CRT (Group 3). And further we divided the
Group 1 and the Group 2 into subgroups according to the vein
resection (Figure 2): Group 1 (surgery first without vein resec-
tion, OP-NVR vs. surgery first with vein resection, OP-VR),
Group 2 (Neo-CRTþOP without vein resection: Neo-OP-NVR
vs. Neo-CRTþOP with vein resection, Neo-OP-VR). Patient
characteristics including perioperative and long-term oncologic
outcomes were analyzed and compared according to the
sequence of Neo-CRT and surgery. This study has been
approved by the Institutional Review Board (IRB) of Severance
Hospital.
Perioperative Assessment of Resectability and
Staging
Preoperative contrast-enhanced computerized tomography
(CT) imaging was performed on the 70 patients, and magnetic
resonance and positron emission tomography (PET)-CT ima-
ging were also performed according to additional necessity.
Venous invasion was defined as tumor-to-vessel circumferential
contiguity that either abutted (50% of the circumference) or
encased (>50% of the circumference) the SMV, PV, or SMV/
FIGURE 1. Flow diagramof the study: Patients were divided into 3
groups according to sequence of Neo-CRT and surgery in 70
patients.PV confluence. Perivascular halo (thin, low-attenuation lesion
circumscribing the vessel) was not considered to be a sign of
vascular invasion. There was fat which separates the tumor from
2 | www.md-journal.comthe vessel, in this case we did not consider it as venous vascular
invasion.31 We measured venous involvement length according
to the coronal view of CT scan images with either tumor
abutment or encasement. We also determined circumferential
involvement by measuring the angle of maximum tumor abut-
ment or encasement. Since the endoscopic ultrasound study
(EUS) rate was 64.3% (45/70), we did not include the data of
EUS finding in this study. Accordingly, we assessed resect-
ability and staging of PC by preoperative contrast-enhanced
CRTþOP group (bold linear line) versus surgery first group (thin
linear line) versus Neo-CRT only group (bold dotted line). Sub-
division of treatment groups.American Joint Committee on Cancer (AJCC) Cancer Staging
Manual, Seventh Edition.32Neoadjuvant Chemoradiation Therapy
Forty-two patients (Groups 2 and 3) who underwent Neo-
CRT received gemcitabine-based chemotherapy. Most of the
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
patients were treated with gemcitabine (1000mg/m2 on days 1,
8, 15, 29, and 36) with concurrent radiotherapy, while some
patients were additionally treated with cisplatin (70mg/m2 on
days 1 and 29) or capecitabine (40mg/m2 on days 1–14 and 21–
35). Radiation therapy, 3-dimensional conformal radiotherapy,
and tomotherapy were applied. Patients’ involved-field irradia-
tion was decided in consideration of gross tumor volume and
generous margin (2 cm) according to the standard protocol of
concurrent chemoradiation therapy (CCRT). In cases when
significant lymph nodes (LNs) were detected at preoperative
examination, we conducted radiotherapy to include LNs as well.
Generally, the 3-field technique, composed of opposed laterals
and an anterior–posterior field, or the 4-field technique were
applied to all patients. As total radiation dose, 45, 50.4, or
58.4Gy was applied with daily fractions of 1.8Gy, 5 days per
week, using a 10MV linear accelerator. Four weeks after
completion of CCRT, chest X-rays and contrast-enhanced CT
scans were conducted according to the World Health Organiz-
ation (WHO) criteria. Treatment response was evaluated using
the Response Evaluation Criteria in Solid Tumors (RECIST).33
After treating patients in an adjuvant or neoadjuvant setting,
we defined a case with both surgery and chemoradiation as
complete treatment and a case with either surgery or chemor-
adiation as incomplete.34–36
Operation Method
Protocols for PD included en-bloc resection and no touch
Medicine  Volume 94, Number 31, August 2015methods. At the time of surgery, when PC adherence to the
SMV, PV, or SMV-PV confluence was encountered, the con-
ductibility of vascular resection was decided according to
TABLE 1. Patient Characteristics According to Sequence of Neo-
Surgery
(n¼ 2
Age Mean (years), range 62.9
Gender Female 14
Male 14
Biliary decompression No 10
Yes 18
CT grade 1 (%) 30.2
CT grade 2 <25% 15
25–50% 9
>50% 4
Venous involvement, mm 9.9
Tumor size at diagnosis, cm 2.55
Clinical stage Stage IIA 16
Stage IIB 12
Initial laboratory findings WBC (103/mL) 6218
Hb (g/dL) 12.3
Platelets (103/mL) 271.5
AST (IU/L) 118.3
ALT (IU/L) 200.4
Albumin (g/dL) 4.04
T. bil (mg/dL) 5.08
ALP (IU/L) 319.0
CA19-9 (U/mL) 503.6
ALP¼ alkaline phosphatase, ALT¼ alanine aminotransferase, AST¼
CT¼ computed tomography, Hb¼ hehemoglobin, Neo-CRT¼ neoadjuva
WBC¼white blood cell.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.adhesion degree between the pancreas and vasculature. If
adhesion was serious and difficult to dissect, we conducted
tangential or segmental vein resection to achieve R0 resection,
regarding the adhesion as potential tumor invasion to venous
vascular structure.
Statistical Analysis
All statistical analyses were performed using IBM SPSS for
Windows, version 20.0 (SPSS, Inc., Chicago, IL). Disease-
specific survival (DSS) was calculated from the time of diagnosis
to death or last follow-up day, and disease-free survival (DFS)was
calculated from the time of surgery to death or last follow-up day.
Survival time was analyzed by the method of Kaplan and Meier.
We compared differences in survival among the 3 groups with the
log-rank test. Patient characteristics, perioperative outcomes, and
oncologic outcomes among the 3 groups were analyzed with the
independent t test for continuous variables and Chi-square test for
categorical variables. And repeated measures data between the
same subjects were analyzed with paired t test. P-values <0.05
were considered statistically significant.
RESULTS
Patient Characteristics
Thirty-seven patients were female, and 33 were male, with
a mean age of 61.7 9.7 years. Among the 70 patients, 28
patients (40%) belonged to Group 1, 30 patients (42.9%) to
Neoadjuvant CRT in BRPCGroup 2, and 12 patients (17.1%) to Group 3. Initial preopera-
tive CT analysis showed tumors abutted to SMV or PV with
34.8 20.8% of total vascular circumference. The mean length
CRT and Surgery
First
8)
Neo-CRTþOP
(n¼ 30)
Neo-CRT Only
(n¼ 12) P-Value
9.62 61.7 8.77 59.0 12.39 0.524
18 5 0.439
12 7
11 3 0.844
19 9
17.3 37.7 23.3 37.5 21.3 0.089
7 5 0.131
15 3
8 4
7.0 13.1 8.1 16.5 5.7 0.033
0.68 2.73 0.65 2.9 0.9 0.377
11 7 0.258
19 5
1989 6384 2490 6603 1738 0.874
1.5 12.3 1.4 12.9 1.7 0.329
94.8 255.7 71.5 264.0 64.3 0.756
137.6 120.4 222.6 81.9 57.2 0.791
211.6 145.8 214.9 162.4 132.1 0.591
0.45 4.02 0.47 4.29 0.36 0.180
5.88 4.35 5.56 3.73 3.50 0.746
281.1 253.3 213.5 205.2 147.5 0.330
829.9 815.8 1451.5 1046 1871.1 0.449
aspartate aminotransferase, CA19-9¼ carbohydrate antigen 19-9,
nt chemoradiation therapy, OP¼ operation, T. bil¼ total bilirubin,
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showed no survival difference (DFS, P¼ 0.414; DSS,
TABLE 2. Operative and Postoperative Characteristics According to Sequence of Neo-CRT and Surgery
Surgery First (n¼ 28) Neo-CRTþOP (n¼ 30) P-Value
Surgical mode PPPD 22 20 0.720
PD 5 7
TP 1 2
DPþ splenectomy 0 1
Vascular resection No 20 9 0.003
Yes 8 21
Operation time, minute 489.1 137.6 514.2 169.8 0.541
Estimated blood loss, mL 1127.5 896.5 1269.0 1079.8 0.591
Transfusion No 13 14 >0.99
Yes 15 16
POPF No 27 27 0.612
Yes 1 3
DGE No 23 19 0.146
Yes 5 11
Ascites No 25 22 0.182
Yes 3 8
Chyle leakage No 25 27 >0.99
Yes 3 3
LOH, days 35.7 14.5 27.0 10.8 0.012
DGE¼ delayed gastric emptying, DP¼ distal pancreatectomy, LOH¼ length of hospital day, Neo-CRT¼ neoadjuvant chemoradication therapy,
OP¼ operation, PD¼ pancreaticoduodenectomy, POPF¼ postoperative pancreatic fistula, PPPD¼ pylorus preserving pancreatic oduodenectomy,
Lee et al Medicine  Volume 94, Number 31, August 2015of venous involvement was 11.7 7.8mm. In comparative
analysis, we found no statistically significant differences in
terms of degree of initial isolated vascular circumference
involvement, tumor size, clinical stage, or laboratory findings
among the 3 groups. However, in terms of length of venous
involvement, Group 1 was significantly shorter (P¼ 0.033,
Table 1).
Perioperative Outcomes
There were no significant perioperative differences
between Groups 1 and 2 (Table 2). However, more frequent
combined vascular resection (P¼ 0.003) was observed in Group
2. Twenty-nine patients underwent venous vascular resection (4
wedge resection, 25 segmental resection of SMV/PV). For
segmental resection, end-to-end anastomosis was performed.
There was no case of anastomosis using graft. Treatment
completeness of systemic chemotherapy was also higher in
Group 2 (P¼ 0.004) because all the patients in Group 2 safely
received preoperative chemotherapy. Delayed gastric empty-
ing (P¼ 0.146), chyle leakage (P¼ 1.000), POPF (P¼ 0.612),
and ascites (P¼ 0.182) were not statistically difference
between Group 1 and Group 2. However, length of hospital
stay (35.7 14.5 days vs. 27.0 10.8 days, P¼ 0.012) was
shorter in Group 2, suggesting that vascular resection and
postoperative complications did not adversely influence
postoperative course.
Short-Term and Long-Term Oncologic Outcomes
Overall R0 resection rate was reported to be 82.8% (48 out
of 58 patients), and Group 2 was found to have higher R0
TP¼ total pancreatectomy.resection rate compared to those of Group 1 (71.4% (20/28) vs.
93.3% (28/30), P¼ 0.038). In addition, smaller pathological
tumor size (P< 0.0001), lower pT stage (P¼ 0.001), and lower
4 | www.md-journal.compTNM stage (P¼ 0.002) were observed in Group 2. Accord-
ingly, Group 2 showed superior DFS compared to Group 1
(P¼ 0.055, Figure 3A). In addition, Group 2 experienced
favorable long-term oncologic outcomes. Mean DSS was noted
to be 30.9 21.46 months in Group 2, followed by 21.3 18.68
months in Group 1, and 19.5 10.41 months in Group 3
(P¼ 0.006, Figure 3B). Notably, when comparing DSS between
Group 1 and Group 3, there was no statistical significant
difference. Only a few long-term survivors were identified in
Group 1 (P¼ 0.991, Figure 3B). And Figure 4 shows the
survival according to the vascular resections. Among the
patients who underwent surgery, PD followed by Neo-CRT
without vascular resection group shows the best DFS and DSS.
And Surgery first with vascular resection group shows the worst
DFS and DSS. Among the Group 1 patients, we analyzed
survival rate according to adjuvant chemotherapy. But thereP¼ 0.394) between those who had received adjuvant che-
motherapy and had not received.
DISCUSSION
Surgical approaches for BRPC can be controversial
because of 2 different definition systems: the University of
Texas MD Anderson Cancer Center (MDACC) criteria23,37 and
the American Hepatopancreatobiliary Association (AHPBA)/
Society of Surgical Oncology (SSO)/Society for Surgery of the
Alimentary Tract (SSAT) criteria.38 In addition, PCwith venous
vascular involvement was once considered as unresectable
clinical condition due to limited surgical techniques and high
mortality rate. However, with advancement in surgical tech-
niques and perioperative management, combined venous vas-
cular resection is regarded as a safe and effective approach for
R0 resection.39 Interestingly, PC with IVVI is generally
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Group 1 (n=28) 
Group 2 (n=30) 
Group 3 (n=12) 
Neo-CRT+OP without vein resection 
Neo-CRT+OP with vein resection   
Surgery first without vein resection   
Surgery first with vein resection 
Group 3 (n=12) 
OP-NVR (n=21) 
OP-VR (n=7) 
Neo-OP-NVR (n=13) 
Neo-OP-VR (n=17) 
FIGURE 3. Subdivision of treatment groups. OP-NVR: surgery first without vein resection; OP-VR: surgery first with vein resection; Neo-
CRTþOP with vein resection.
FIGURE 4. Oncologic outcomes according to sequence of Neo-
CRT therapy and surgery with or without vein resection. (A)
Disease-free survival and (B) disease-specific survival. Survival
differences according to sequence of Neo-CRT and surgery with
or without vein resection. Bold linear line: Neo-CRTþOP without
Medicine  Volume 94, Number 31, August 2015 Neoadjuvant CRT in BRPCregarded as potentially resectable PC according to MDACC
criteria but only borderline resectable based on NCCD guide-
lines. Therefore, the surgical approach applied in these cases
varies substantially. However, according to our surgical experi-
ences of PC with IVVI, we would like to support the rationale of
preoperative Neo-CRT followed by radical pancreatectomy
with the following reasons.
Proper Selection
As shown in Figure 1, there were 12 patients who did not
undergo pancreatectomy following Neo-CRT. This was
because disease progressed during Neo-CRT, which acted as
the window period for metastatic disease.37 Theses patients had
high possibility of early recurrence and disease progression
even after upfront surgery. As such, long-term favorable onco-
logic outcomes would not be expected for these patients.
Therefore, Neo-CRT could play a role as one of the currently
available tools for detecting patients who will be benefited from
major pancreatectomy; such tools may be regarded as person-
alized surgical approaches to PC.40 The excellent survival
outcomes in the present study indirectly support the potential
benefit of proper patient selection by Neo-CRT. Interestingly,
survival outcomes were similar in Group 1 and Group 3. Only a
few long-term survival cases were found in Group 1, suggesting
Neo-CRT without surgery also can provide acceptable onco-
logic outcome to most unresected patients with PC with IVVI.
Complete Treatment
Because PC is a systemic disease, it is difficult to expect
improvement of oncologic outcome with surgery only.10 Adju-
vant CRT created momentum for treating pancreas cancer.
However, in the clinical setting of postoperative adjuvant
treatment, problems often arose with ensuring appropriate
timing for systemic treatment due to delayed postoperative
recovery or medical comorbidity.11,14,15 That is, the possibility
of preventing high loco-regional recurrence rates and distant
metastasis was decreased because CRT could not be performed
as needed after surgery. Therefore, Neo-CRT was proposed as a
new method for systemic treatment for pancreas cancer, pro-
viding patients with conditions to receive adequate CRT and
thereby enabling high completeness of treatment by combining
systemic treatment with local treatment.16,22,23 Among patients
who underwent operation after Neo-CRT, there were several
cases where patients also received adjuvant treatment; the rate
OP-NVR: Neo-CRTþOP without vein resection; Neo-OP-VR: Neo-of postoperative adjuvant therapy showed no statistically sig-
nificant difference between Groups 1 and 2 (P¼ 0.825,
Table 3). However, considering patients in Group 2 received
veinresection (Neo-OPNVR); Thin linear line: Neo-CRTþOP with
vein resection (Neo-OPVR); Bold dotted line: surgery first without
vein resection (OP-NVR); Dashed dotted line: surgery first with
vein resection (OP-VR); Dashed line: Neo-CRT only.
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TABLE 3. Pathologic Characteristics According to Inclusion or Exclusion of Neo-CRT
Surgery First (n¼ 28) Neo-CRTþOP (n¼ 30) P-Value
Pathologic tumor size, cm 2.74 0.65 1.74 1.14 <0.001
Pathological stage Stage 0 0 3 0.002
Stage IA 0 5
Stage IB 0 3
Stage IIA 11 5
Stage IIB 17 14
T-stage T0 0 3 0.001
T1 0 5
T2 0 2
T3 28 20
T4 0 0
N-stage N0 11 16 0.284
N1 17 14
Perineural invasion No 9 8 0.745
Yes 19 14
Lymphovascular invasion No 17 17 0.210
Yes 11 4
Postoperative adjuvant therapy No 7 8 0.825
Yes 21 22
Treatment completeness (%) No 7 0 0.004
Yes 21 30
Radicality (resection status) R0 20 28 0.038
R1 8 2
R2 0 0
TABLE 4. Pathologic Characteristics According to Vein Resec-
tion
No Vein
Resection
(n¼ 26)
Vein
Resection
(n¼ 32) P-Value
Pathological stage Stage 0 0 3 0.120
Stage IA 2 3
Stage IB 1 2
Stage IIA 7 9
Stage IIB 16 15
T-stage T0 0 3 0.082
T1 2 3
T2 0 2
T3 24 24
T4 0 0
N-stage N0 10 17 0.266
N1 16 15
Perineural invasion No 11 6 0.020
Yes 10 23
Lymphovascular
invasion
No 15 19 0.788
Yes 6 9
Radicality R0 19 29 0.078
Lee et al Medicine  Volume 94, Number 31, August 2015preoperative Neo-CRT as systemic treatment before surgery,
this group underwent both systemic and local treatment. As
such, Group 2 (100%) was superior to Group 1 (75%) in terms
of completeness of treatment (P¼ 0.004, Table 3).37
Therapeutic Effect
Our study shows that there were several positive treatment
effects for patients with BRPC with IVVI who underwent
pancreatectomy after Neo-CRT. The positive treatment effects
include downstaging.35,37,41,42
In Group 1, tumor size at diagnosis was 2.55 0.68 cm,
and postoperative pathologic tumor size was 2.73 0.65 cm,
which shows no significant difference before and after surgery
on paired t test (P¼ 0.244). On the other hand, the tumor size in
Group 2 was 2.70 0.84 cm at diagnosis, however, at post-
operative pathologic tumor size was 1.74 1.14 cm, which is
statistically significant (P¼ 0.003). These results suggest a
tumor reducing effect of Neo-CRT. There were no statistically
significant differences in terms of clinical T stage or clinical
TNM stage between Groups 1 and 2. However, pathological
examination showed downstaging effect37 in T stage (P¼
0.001) and pTNM stage (P¼ 0.002) in Group 2 (Table 3).
There was no significant difference in LN metastasis in our
study; however, several studies have suggested that Neo-CRT is
effective for reducing LN metastasis.14,22,23,41 Considering LN
metastasis as a poor prognostic factor in PC,43 we can expect a
potential treatment role for Neo-CRT for LN metastasis.41
The present study (Table 3) showed higher R0 resection
Neo-CRT¼ neoadjuvant chemoradication therapy, OP¼ operation.rate in Group 2 (71.4% vs. 93.3%, P¼ 0.038). In Group 2 with
pancreatectomy following Neo-CRT, combined vascular resec-
tion was frequent (P¼ 0.003). Our surgical policy indicates
(resection status)
R1 7 3
R2 0 0
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en-bloc resection method for suspicious cancerous lesions
invading or severely abutting a major venous vascular structure.
In the past, IVVI of the resection resulted in high operative
mortality rate.24,26 However, combined venous vascular resec-
tion became feasible and safe without increasing the morbidity
and mortality due to improvements in surgical experience,
techniques, and perioperative management.39 In recent years,
there has been no reported difference in oncologic outcomes in
patients with or without combined venous vascular resec-
tion.28,29 In our study, although Group 2 received more vein
resection, there was no statistically significant difference
between Group 1 and Group 2 in terms of operation time
(P¼ 0.541), estimated blood loss (P¼ 0.591), or transfusion
(P¼ 1.000). In addition, Group 2 showed significantly shorter
length of hospital day (LOH) (P¼ 0.012). Therefore, it seems
that combined venous vascular resection does not adversely
Medicine  Volume 94, Number 31, August 2015impact short-term or long-term oncologic outcome. For R0
resection, combined venous vascular resection should be
actively considered.39,41,44,45
FIGURE 5. Survival rates of patients with surgical treatment
according to vein resection. (A) Disease-free survival and (B)
Disease-specific survival. Bold linear line: without vein resection;
Thin linear line: with vein resection.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.We analyzed survival rate among the patients underwent
surgery according to the vein resections (Figure 2). The con-
dition of vascular involvement was followed by the NCCN
guidelines. And the vein resection was performed in case when
adhesion was too serious to be dissected from pancreas to
vessel. When we compare the pathologic characteristics accord-
ing to vein resection, the perineural invasion was found more in
patients with vein resection (P¼ 0.020) than without vein
resection (Table 4). But the survival rate was not different
between patient with vein resection and without vein resection
(Figure 5). We divided the Group 1 and the Group 2 into
subgroups according to the vein resection. The OP-VR group
showed the worst DFS and DSS than those of Group 3
(Figure 4). However, Group 2, regardless of the vein resection,
achieved better survival outcomes than Group 1. These results
suggest the usefulness of Neo-CRT in borderline resectable
pancreatic cancer (BRPC) linked to IVVI.
This study was conducted retrospectively by a single
institution with a limited number of patients. To determine
more proper approach to BRPC with IVVI patients, multi-
institutional study based on a standardized surgical protocol
should be perform. In this context, Intergroup Trial led by the
Alliance for Clinical Trials in Oncology, National Cancer
Institute cooperative group is performing a pilot study to test
the feasibility of induction therapy with FOLFIRINOX followed
by 5-FU-based chemoradiation for patients with BRPC.46,47
This study will provide momentum for future clinical trials
based on well-standardized consensus in terms of definition and
perioperative surgical treatments of BRPC.46,47
In conclusion, upfront PD with combined venous vascular
resection is technically feasible and safe for patients with PC
with IVVI. However, our experiences indicate that PD with
combined venous vascular resection following Neo-CRT pro-
vides excellent survival outcomes; in some cases, avoiding
unnecessary major operations. These favorable oncologic
benefits may result from multifactorial effects of preoperative
Neo-CRT, such as proper patient selection, complete treatment,
and therapeutic effect.
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